How a German Biotech's Novel Approach Just Secured Major Seed Funding

Jan de Vries · 2026-08-28

There's a fresh player on the European biotech scene, and they've just hit a significant milestone. Revier Therapeutics, a startup based in Heidelberg, Germany, has officially launched with a $6.5 million seed financing round. This isn't just another funding announcement—it represents a major bet on a new scientific strategy aimed at some of the world's most persistent heart and metabolic diseases. They're focusing on cardiometabolic disorders, which is a fancy term for the dangerous intersection of heart disease and metabolic problems like diabetes. It's a massive, and growing, global health challenge. ### The Science Behind the Strategy So, what makes this company different? They're going after a specific family of enzymes called class IIa HDACs. Think of these enzymes like switches inside our cells. Sometimes, in disease, these switches get stuck in the 'on' position, driving the illness forward. Previous attempts to target HDACs were a bit like using a sledgehammer. They hit all the switches—the bad ones and the essential, good ones—leading to serious side effects that limited how much medicine a patient could take. Revier's approach is more like a precision lockpick. Their orally available small molecules are designed to selectively inhibit only the disease-driving activity of class IIa HDACs. The goal is to turn off the pathogenic switch while leaving the healthy, necessary functions completely alone. It's a tricky balancing act, but if they pull it off, it could mean effective treatments with a much better safety profile. Here's what they're targeting first: - **HFpEF (Heart Failure with Preserved Ejection Fraction)**: A particularly stubborn form of heart failure where the heart muscle stiffens. Treatment options are frustratingly limited. - **ASCVD (Atherosclerotic Cardiovascular Disease)**: The plaque buildup in arteries that leads to heart attacks and strokes. Prof. Eva van Rooij, PhD, the company's co-founder and CEO, put it plainly. "Millions of patients still face limited options," she said. "We believe the next generation of medicines needs to address the underlying disease-driving biology." ### Why Investors Are Betting on This Team The $6.5 million seed round was led by the KHAN Technology Transfer Fund II, with key participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors via Revier Invest Heidelberg. It's a coalition that blends deep-tech venture capital with strong regional support. Michael Hamacher from KHAN highlighted the team as a critical factor. "Combined with an exceptional leadership team and deep scientific expertise," he noted, "the company has a unique opportunity to reshape the standard of care." That scientific firepower comes from founders like Prof. Johannes Backs, MD, who explained the core advantage. "Revier’s first-in-class molecules selectively target class IIa HDACs... This precise mode of action is designed to be therapeutically effective while maintaining a beneficial safety profile." ### What's Next for the Capital? The new funding has a clear job. It's fuel to push their preclinical pipeline toward the clinic. That means advancing their lead program for HFpEF and their second program for ASCVD. The money will also help them build out the full team—operations, science, and clinical functions—needed to transition from a research-stage company to one testing its therapies in humans. For professionals watching the European startup ecosystem, especially in life sciences, this is a launch worth noting. It showcases how deep scientific innovation in academic hubs like Heidelberg can attract serious capital to tackle unmet medical needs. The path from lab to patient is long and fraught with challenges, but Revier Therapeutics is now officially on its way, backed by a compelling strategy and the resources to start proving it.